MHRA recommends that sildenafil is made available over the counter in the UK.
Full-time freelance journalist, who works mostly for The Guardian, writing across the Society Guardian spectrum. For more than 10 years Debbie wrote a public sector careers column for the paper and website. Debbie began her career more than 20 years ago as a general reporter on the South London Press moving on to reporting jobs with the Sunday People, the Evening Standard and GP magazine where she was deputy news editor until 2000 when she became a full-time freelance. Her book, ‘How to change your career’ was published by Guardian Books in 2007.
A public consultation is open until 18 April 2017 concerning the reclassification of sildenafil — more commonly known as Viagra — as a P medicine for treatment of erectile dysfunction.
Source: GeoPic / Alamy Stock Photo.
The MHRA proposes that 50mg sildenafil citrate tablets should be available from pharmacies for use by adult men with erectile dysfunction.
Sildenafil — the prescription-only medicine branded as Viagra for the treatment of erectile dysfunction — could become a pharmacy (P) medicine if government proposals go ahead.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), which regulates medicines and medical devices in the UK, is recommending that the drug — which was first made available in the UK in 1998 — should be reclassified as a P medicine.
The recommendation, which is now out for pubic consultation until 18 April 2017, follows a request from the drug’s manufacturer Pfizer that the product should be more easily accessible.
The MHRA proposes that 50mg sildenafil citrate tablets should be available in pharmacies for use by adult men with erectile dysfunction. The consultation document also says that the recommended maximum pack size is eight tablets and the drug should be taken as a maximum daily dose of 50mg.
It adds, however: “This proposal does not change any of the conditions of supply of the currently available prescription products for erectile dysfunction — which will remain available on prescription.”
Pfizer has produced a checklist for pharmacists to use when supplying the product, which includes the recommendation that it should not be sold to men with diagnosed cardiovascular conditions.
The consultation document says: “Pharmacy availability of sildenafil tablets would be of value to men who suffer from erectile dysfunction. Patients can be assessed for suitability by a pharmacist and made aware of the risks, situations where supply is not appropriate and potential interactions with other drugs.
“The risks of indirect danger arising from missed diagnosis of underlying disease is minimised through the pharmacist using their professional judgement and the checklist to identify patients for whom the product is not suitable, and referring these patients to a doctor,” it adds. “It is also considered that there is a low risk of direct danger and of intentional abuse that will lead to a danger to human health.”
The MHRA highlights the benefits that pharmacy supply of sildenafil would bring, which it says outweighs the risks involved, “bringing a hard to reach group into healthcare environment with the potential to increase earlier identification of heart disease and also reducing the risks associated with use of counterfeits obtained via the internet”.
Berkeley Phillips, medical director at Pfizer UK, says reclassifying the product as a P medicine “could offer men a new and additional way to access a legitimate, long established, and well-studied treatment for erectile dysfunction”.
“This could have further benefits as the condition may be an early warning sign of a more serious underlying condition, such as heart disease, which may otherwise go undetected,” he adds.
The company confirmed that if the proposal goes ahead the product will also still be available on prescription.
The Royal Pharmaceutical Society (RPS), the professional leadership body for pharmacists in Great Britain, supports the MHRA’s reclassification proposal. Martin Astbury, its president, says: “The potential switch… increases access to a medicine that has been proven to be safe and effective when used appropriately through over a decade of real-world use by millions of men.”
He adds that the move will help identify more men who may be at risk of cardiovascular disease whom pharmacists will be able to refer to GPs. “It will also help improve medicines safety as sildenafil is one of the most counterfeited medicines.”
If the product is reclassified, Astbury says the RPS will provide advice and guidance to pharmacists about the treatment of erectile dysfunction.
Citation: The Pharmaceutical Journal , Vol 298, No 7900, online | DOI: 10.1211/PJ.2017.20202527.
Have your say.
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.
Recommended from Pharmaceutical Press.
Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017 (The Orange Guide)
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.
Reviews over-the-counter medicines, arranged by the conditions they are licensed to treat. Includes product recommendations.
Rules and Guidance for Pharmaceutical Distributors 2017 (The Green Guide)
Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.
Health Economics is a practical analysis of the prominent economic issues facing the American health care system, and what mechanisms exist to counter it.
Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.
Nurse Prescribers’ Formulary.
Essential reference for Community Practitioner Nurse Prescribers. Provides an overview of common conditions and details of medicines that may be prescribed.
Search an extensive range of the world’s most trusted resources.
Viagra prescriptions almost triple in a decade.
Reclassifying erectile dysfunction drug sildenafil as a P medicine not such a huge leap.
Three decades of Viagra.
Why the resurgence of POM-to-P reclassifications in the UK is a good thing.
Jobs you might like.
Pre-Registration Trainee – Poplar Poplar, E14 0BE.
PRE-REG STUDENTS FOR 2017-2018 SW LONDON LONDON SW13 and SW14.
Clinical Pharmacist (General Practice) – 3 positions available The postholder will work across up to 4 General Practices within Central London.
Chief Officer Derbyshire.
Pre-reg Trainee 1. SE1 6ED, London (Greater) 2 . SE1 7BL, London (Greater)
International and intergovernmental organisations.
Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.